Tyra Biosciences, Inc.

NasdaqGS:TYRA Stock Report

Market Cap: US$1.9b

Tyra Biosciences Management

Management criteria checks 4/4

Tyra Biosciences' CEO is Todd Harris, appointed in Aug 2018, has a tenure of 7.75 years. total yearly compensation is $5.57M, comprised of 11.8% salary and 88.2% bonuses, including company stock and options. directly owns 2.28% of the company’s shares, worth $44.11M. The average tenure of the management team and the board of directors is 3.9 years and 5.8 years respectively.

Key information

Todd Harris

Chief executive officer

US$5.6m

Total compensation

CEO salary percentage11.82%
CEO tenure7.8yrs
CEO ownership2.3%
Management average tenure3.9yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Analysis Article • Oct 01

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 28

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

Summary Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated better safety and tolerability compared to erdafitinib, with fewer high-grade toxicities and lower incidence of hyperphosphatemia and other side effects. Financially, Tyra has a market cap of $632mn, a cash balance of $360mn, and a cash runway of 11–20 quarters, depending on expenses. The market's reaction to TYRA-300's data was mixed; further data from the SURF301 trial is needed to make a definitive investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Dec 17

The Take On Tyra Biosciences

Summary Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg. TYRA-300 aims to overcome limitations of existing mUC therapies like Balversa, with ongoing trials at higher 120mg doses and other cancer/genetic indications. Despite safety concerns, analysts remain bullish on Tyra, with unanimous Buy ratings and price targets between $28 and $33 per share. RA Capital Management increased its stake in Tyra, signaling confidence, but the path to first-line therapy approval remains uncertain pending further data. An analysis around Tyra Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Dec 11

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 21

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights Tyra Biosciences' estimated fair value is US$25.61 based on 2 Stage Free Cash Flow to Equity Tyra...
Seeking Alpha • Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Summary Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. TYRA has a strong cash position, with $373.8 million as of June 30, 2024, sufficient to fund operations into 2026. Read the full article on Seeking Alpha
Analysis Article • Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 23

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Summary Tyra Biosciences, Inc. has no revenue or earnings, but share prices have increased by 32.68% in the past year. The company focuses on precision medicines targeting FGFR biology, with future promise in oncology and genetic conditions. Despite bullish signals, the lack of key fundamentals makes Tyra a speculative play, rated as a Hold with potential for growth. Read the full article on Seeking Alpha
Analysis Article • Jul 05

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights The projected fair value for Tyra Biosciences is US$18.25 based on 2 Stage Free Cash Flow to Equity Tyra...
Analysis Article • May 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 27

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 13

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tyra Biosciences...
Analysis Article • Feb 23

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 09

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

Tyra Biosciences GAAP EPS of -$0.36

Tyra Biosciences press release (NASDAQ:TYRA): Q2 GAAP EPS of -$0.36. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million.
Analysis Article • Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Todd Harris's remuneration changed compared to Tyra Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$131m

Dec 31 2025US$6mUS$658k

-US$120m

Sep 30 2025n/an/a

-US$112m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$8mUS$633k

-US$86m

Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$75m

Dec 31 2023US$5mUS$608k

-US$69m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$51m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$2mUS$581k

-US$55m

Sep 30 2022n/an/a

-US$52m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$6mUS$443k

-US$26m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$350k

-US$9m

Compensation vs Market: Todd's total compensation ($USD5.57M) is about average for companies of similar size in the US market ($USD5.47M).

Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.

CEO

Todd Harris (46 yo)

7.8yrs
Tenure
US$5,566,997
Compensation

Dr. Todd Harris, Ph D., co-founded Tyra Biosciences, Inc. and serves as President and Chief Executive Officer since November 2018 and Director since August 2018 and had been its Secretary November 2018 and...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Harris
Co-Founder7.8yrsUS$5.57m2.28%
$ 44.1m
Bhavesh Ashar
Chief Operating Officerless than a yearUS$5.19mno data
Douglas Warner
Chief Medical Officer1.7yrsUS$2.37m0%
$ 0
Daniel Bensen
Co-Founder & Chief Discovery Officer7.8yrsUS$2.66m0.25%
$ 4.8m
Alan Fuhrman
Chief Financial Officer3.3yrsUS$3.53m0.027%
$ 524.8k
Julia Rueb
VP of Finance & Principal Accounting Officerless than a yearno datano data
Robert Hudkins
Chief Technology Officer5.3yrsno datano data
Ronald Swanson
Chief Scientific Officer6.3yrsUS$2.53mno data
Ali Fawaz
General Counsel & Secretary4yrsUS$2.76mno data
Sarah Honig
Senior VP of Corporate Development & Strategy3.8yrsno datano data
Liz Pagano
Chief Human Resources Officer1.9yrsno datano data
Piyush Patel
Chief Development Officer5.3yrsno datano data
3.9yrs
Average Tenure
56yo
Average Age

Experienced Management: TYRA's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Todd Harris
Co-Founder7.8yrsUS$5.57m2.28%
$ 44.1m
Robert J. More
Independent Director7.5yrsUS$232.67k0%
$ 0
Peter Smith
Scientific Advisorno datano datano data
Gilla Kaplan
Independent Director7.2yrsUS$197.06k0.047%
$ 916.6k
William Hahn
Scientific Advisorno datano datano data
Jeffrey Hager
Scientific Advisorno datano datano data
Rehan Verjee
Independent Director4.9yrsUS$205.57k0%
$ 0
S. Rothenberg
Independent Director2yrsUS$192.47k0%
$ 0
Melissa McCracken
Independent Director5.2yrsno datano data
Jake Simson
Independent Director6.3yrsUS$203.54k0%
$ 0
Susan Moran
Independent Director2yrsUS$203.27k0%
$ 0
Jason Sheltzer
Scientific Advisorno datano datano data
5.8yrs
Average Tenure
55yo
Average Age

Experienced Board: TYRA's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 20:15
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tyra Biosciences, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Jason ZemanskyBofA Global Research
John NewmanCanaccord Genuity